K-numberK251230
Device nameThe Alma Hybrid Laser System
ApplicantAlma Lasers, Inc.
Product codeGEX
Device classClass II
Decision dateMay 21, 2025
DecisionSubstantially Equivalent
Regulation878.4810
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Alma Hybrid Laser System is a multi-wavelength surgical laser (CO2 at 10600 nm and 1570 nm) designed for ablation, vaporization, excision, incision, and coagulation of soft tissue across multiple medical specialties including dermatology, plastic surgery, podiatry, gynecology, neurosurgery, orthopedics, otolaryngology, general surgery, dental/oral surgery, and genitourinary procedures. It features fractional and non-fractional applicators (Pixel, HyLight, and ProScan) for performing skin resurfacing, scar treatment, lesion removal, and other surgical applications.

Technological characteristics

The device has identical wavelengths (10600 nm and 1570 nm), pilot beam specifications (650 nm, 3 mW), operation modes (repeat pulse/continuous wave), spot sizes (0.15–3.1 mm for HyLight; 0.125–0.20 mm pixels for Pixel), repetition rates (1–5 Hz), pulse durations (10–1000 ms), and maximum fluence parameters compared to the primary predicate K203441. Output power is 30 W or 70 W in both systems. ProScan applicator specifications match the predicate in scan diameter (up to 30 mm) and output energy (24–144 mJ/pixel).

Test standards cited

IEC 60601-1, IEC 60601-1-2, IEC 60601-2-22, IEC 60825-1, ISO 10993-1, ISO 17665-1, IEC 62304, and ISO 14971. Testing was performed under the previous clearance K230441.

Substantial equivalence argument

The subject device shares identical technological parameters (wavelengths, power outputs, spot sizes, repetition rates, and fluence characteristics) with the primary predicate K203441 and uses the same laser principles. The device has the same intended use (surgical soft tissue ablation/vaporization/coagulation) and the same or expanded indications covering multiple surgical specialties. Risk assessment and supporting documentation demonstrate that changes do not affect safety and effectiveness, and no new testing beyond the previously cleared submission is required. Because the technical design, operation, and indications are substantially identical to the predicate, substantial equivalence is established.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →